Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises

NCT01895361 is registered in ClinicalTrials.gov with Reprixys Pharmaceutical Corporation as lead sponsor.

NCT NCT01895361
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01895361 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Blind, 12-Month Study to Assess Safety and Efficacy of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Sickle Cell-Related Pain Crises
Lead sponsor
Reprixys Pharmaceutical Corporation
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2013
Completion date
March 31, 2016
Enrollment
198 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

sickle cell disease